Skip to main content
Vivo Bio tech Ltd. logo

Vivo Bio tech Ltd. — Investor Relations & Filings

Ticker · 511509 ISIN · INE380K01017 LEI · 98450079E4M2CR80D882 BSE.NS Professional, scientific and technical activities
Open in API
Filings indexed 440 across all filing types
Latest filing 2023-09-08 Annual Report
Country IN India
Listing BSE.NS 511509

About Vivo Bio tech Ltd.

http://www.vivobio.com/

Vivo Bio Tech Ltd. is a preclinical Contract Research Organization (CRO) providing comprehensive drug discovery and development services. The company specializes in conducting in vivo preclinical studies, including toxicology, pharmacology, and pharmacokinetic evaluations. It operates advanced facilities for the breeding and distribution of Specific Pathogen Free (SPF) laboratory animal models, maintained through strategic partnerships with global leaders like Taconic Biosciences. Vivo Bio Tech offers regulatory-compliant services such as safety assessment, efficacy testing, and specialized research models to support pharmaceutical and biotechnology sectors. Its operations are characterized by adherence to Good Laboratory Practice (GLP) standards and AAALAC accreditation, ensuring high-quality data for global regulatory submissions.

Recent filings

Filing Released Lang Actions
Vivo Bio Tech Limited has submitted with the exchange the Annual Report of the Company for the financial year 2022-2023.
Annual Report Classification · 100% confidence The document is a detailed Annual Report for the financial year 2022-2023 of Vivo Bio Tech Limited. It includes a corporate overview, statutory reports, financial statements, management discussion and analysis, corporate governance report, and detailed financial data such as revenue, EBITDA, net profit, RoCE, and other financial metrics. The document references the Notice of the 36th Annual General Meeting (AGM) and the Annual Report itself, but the content provided is the full Annual Report, not just an announcement or a notice. The length of the document (15,000 characters) and the presence of comprehensive financial and operational information confirm it is the full Annual Report. Therefore, the correct classification is Annual Report (10-K).
2023-09-08 English
Vivo Bio Tech Limited has submitted with the exchange, the copies of Newspaper Publication for intimation on convening of 36th Annual General Meeting of the Company and Updating/Registering ....
AGM Information Classification · 95% confidence The document is a letter addressed to BSE Limited regarding the newspaper publication for the intimation of conducting the 36th Annual General Meeting (AGM) of the company through Video Conferencing/Other Audio Visual Means (VC/OAVM). It references compliance with SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015, specifically Regulation 30, which pertains to disclosures of material events. The content is about announcing the AGM date, mode, and related procedural information, not the AGM materials themselves or the voting results. The document is a notification or announcement about the AGM, specifically the newspaper publication of the AGM notice. It does not contain the AGM presentation, voting results, or financial reports. Therefore, the most appropriate classification is AGM Information (AGM-R), as it relates to information shared about the AGM event itself.
2023-09-02 English
Vivo Bio Tech Limited has submitted with the exchange, the copies of Newspaper Publication for intimation on convening of 36th Annual General Meeting of the Company and Updating/Registering ....
AGM Information Classification · 95% confidence The document is a letter addressed to BSE Limited regarding the newspaper publication for the intimation of conducting the 36th Annual General Meeting (AGM) of the company through Video Conferencing/Other Audio Visual Means (VC/OAVM). It references compliance with SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015, specifically Regulation 30, which pertains to disclosures of material events. The document includes no financial data or detailed report content but is an announcement about the AGM and the manner of registering/updating email IDs of members. The document length is about 15,000 characters but the content is essentially an announcement of the AGM and related procedural information, not the AGM materials or minutes themselves. Therefore, this document fits the category of AGM Information (AGM-R), which covers presentations and materials shared during the AGM or announcements related to the AGM. Given the content is about the intimation and arrangements for the AGM, AGM Information is the best fit with high confidence.
2023-09-02 English
Vivo Bio Tech Limited has informed the exchange regarding the Book Closure for the purpose of 36th Annual General Meeting of the Company
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a short notice informing about the book closure dates for the 36th Annual General Meeting (AGM) of the company. It references Regulation 42 of SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015, which pertains to intimation of book closure for shareholder meetings. The document does not contain any financial data, detailed report, or presentation material. It is an announcement related to the AGM but not the AGM materials themselves. Given the short length (1504 characters) and the nature of the content, this fits the category of Declaration of Voting Results & Voting Rights Announcements (DVA) or possibly a Regulatory Filing (RNS). However, since it specifically relates to book closure for the AGM, which is a procedural announcement related to shareholder voting rights, the best fit is DVA. Confidence is high due to clear reference to book closure and AGM date.
2023-08-31 English
Vivo Bio Tech Limited has informed the exchange that Mr. Shyam Sunder Tipparaju was appointed as an Additional Director designated as Non-Executive and Independent Director on the Board of the Company
Board/Management Information Classification · 100% confidence The document is a formal announcement addressed to a stock exchange (BSE Limited) regarding the appointment of a new Additional Non-Executive Independent Director, Mr. Shyam Sunder Tipparaju. It references compliance with SEBI Listing Obligations and Disclosure Requirements Regulations, specifically Regulation 30, which pertains to disclosures about changes in directors and key managerial personnel. The document includes details about the appointment, the director's profile, and confirms no relationship with existing directors. There are no financial statements, earnings data, or report publications. This fits the category of Board/Management Information (MANG), which covers announcements of changes in the company's board of directors or senior management.
2023-08-31 English
Vivo Bio Tech Limited has informed the exchange regarding the resignation of Mr. Hariharan Ravindran as an Independent Director of the Compamy w.e.f. August 31, 2023.
Regulatory Filings
2023-08-31 English

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.